In peptic ulcer therapy the search ends here



Prescribing Information

Presentation: Antepsin Tablets 1 gram are white, oblong, biconvex, uncoated tablets scored and engraved 1239 on one side and Ayerst on the other. Each tablet contains 1 gram sucralfate, a basic aluminium salt of sucrose octasulphate. **Uses:** For the treatment of duodenal ulcer, gastric ulcer and chronic gastritis. **Dosage and Administration:** For oral administration. Adults – Usual dose 1 gram 4 times a day to be taken one hour before meals and at bedtime. Maximum daily dose 8 grams. Four to six weeks treatment is usually needed for ulcer healing but up to twelve weeks may be necessary in resistant cases. Antacids may be used as required for relief of pain, but should not be taken half an hour before or after Antepsin. Elderly – There are no special dosage requirements for elderly patients but as with all medicines the lowest effective dose should be used. Children – Safety and effectiveness in children have not been established. **Contra-Indications, Precautions, Warnings, etc.** *Contra-indications:* There are no known contra-indications. *Precautions:* 1. The product should only be used with caution in patients with renal dysfunction. 2. Although animal reproductive studies show no evidence of foetal malformations, safety in pregnant women has not been established and Antepsin should be used during pregnancy only if clearly needed. 3. It is not known whether this drug is excreted in human milk. Caution should be exercised when Antepsin is administered to a nursing woman. *Drug Interactions:* Concomitant administration of Antepsin may reduce the bio-availability of certain drugs as has been observed in animal studies with tetracycline, phenytoin and cimetidine, and in human studies with digoxin. Administration of Antepsin with any of these drugs should be separated by two hours. Since Antepsin may hinder warfarin absorption, caution should be exercised when these two drugs are used together. *Side Effects:* A low incidence of mild side effects, e.g. constipation, has been reported. *Overdosage:* There is no experience in humans with overdosage. Acute oral toxicity studies in animals, however, using doses up to 12g/kg body weight, could not find a lethal dose. Risks associated with overdosage should, therefore, be minimal. **Pharmaceutical Precautions:** No special requirements for storage are necessary. **Legal Category:** POM. **Package Quantities:** Antepsin 1 gram – Securitainers of 100. **Product Licence Numbers:** PL No. 0607/0045. PA No. 149/4/2. **Basic N.H.S. Price:** Average daily cost 50p.

*ANTEPSIN is a registered trade mark

Further information is available on request to the Company

Date of preparation January 1985

Ayerst International
Ayerst Laboratories Ltd.
South Way, Andover, Hampshire SP10 5LT
Telephone: Andover (0264) 58711

Distributors in Ireland: Ayerst Laboratories Ltd.
765 South Circular Road, Islandbridge, Dublin 8

Gastrozepin is a selective antimuscarinic agent which provides balanced control of gastric secretion without markedly affecting other peripheral receptor sites. This gastro-selective action means that, in practice, Gastrozepin is a well-tolerated drug which heals peptic ulcers.

Gastrozepin DOES NOT . . .
- **rely on acid reduction alone**
- **rely on pepsin reduction alone**
- **rely on mucosal protection alone**
- **profoundly affect intragastric pH**

Gastrozepin DOES . . .
- **relieve daytime pain**
- **relieve night-time pain**
- **reduce antacid intake**
- **heal peptic ulcers with one 50 mg tablet b.d.**

For the treatment of peptic ulcer

Twice daily

GASTRO SELECTIVE

Gastrozepin®

pirenzepine

The gastro-selective anti-secretory

Prescribing Information: Presentation: White tablets each containing 50 mg of pirenzepine dihydrochloride scored on one face with 'G' on one side of the score and '50' on the other. The obverse is impressed with the symbol. **Uses:** Gastrozepin is indicated in the treatment of gastric and duodenal ulcers. **Dosage:** 50 mg at bedtime and, in the morning before meals. In severe cases the total daily dose may be increased to 150 mg in divided doses. Continuous therapy may be recommended for up to three months. **Contra-indications, Warnings etc:** Interaction with sympathomimetics and monoamine oxidase inhibitors and Gastrozepin is a theoretical possibility. Gastrozepin is not recommended during pregnancy although animal experiments no teratogenic effects were noted. Breast milk concentration after therapeutic doses is unlikely to affect the infant. Side effects: occasionally transitory dry mouth and accommodation difficulty may occur. Treatment of overdosage: entirely symptomatic. There is no specific antidote. **Basic NHS price:** 50 mg tablets: 60 £20.50. **Product Licence No.:** 50 mg tablets: PL 0015 0161.

Further information available on request.
The Boots Company PLC, Nottingham.

Gastrozepin® Trade Mark

HEALING POWER WHEN IT'S NEEDED MOST IN DUODENAL ULCER



Acid attack at night is now known to be one of the most important factors in the formation of duodenal ulcers.

'Tagamet' 800 mg at bedtime effectively controls this damaging nocturnal acid without disturbing the patient's normal daytime gastric physiology.

One 'Tagamet' 800 mg tablet at bedtime for four weeks is the recommended healing regimen for all duodenal ulcer patients.

And the results are impressive... 'Tagamet' 800 mg completely healed 79 per cent of duodenal ulcers in four weeks and 96 per cent in eight weeks[1] whilst providing prompt and effective relief from both daytime and night-time pain.

With 'Tagamet' 800 you can offer your patients healing power precisely when it's needed.

TAGAMET CIMETIDINE 800

One tablet at bedtime for four weeks

Reference 1. Lambert R. In: 'Tagamet.' New Dimensions. A Symposium Proceedings. XII Int Cong Gastroenterol, Lisbon, 1984;15-23.

Prescribing Information. Presentations 'Tagamet' Tablets, each containing 800 mg cimetidine (PL 0002/0128: 28 tablets, £15.78) or 400 mg cimetidine (PL 0002/0092: 56 tablets, £16.61). 'Tagamet' Syrup, containing 200 mg cimetidine per 5 ml (PL 0002/0073: 500 ml, £19.20). **Indication** Duodenal ulcer. **Dosage** *Usual dosage: Adults. Duodenal ulcer,* 800 mg once a day at bedtime, or 400 mg b.d. with breakfast and at bedtime. To prevent relapse, 400 mg at bedtime or 400 mg morning and at bedtime. *Elderly:* As above unless markedly impaired renal function. *N.B. For full dosage instructions see Data Sheet.* **Cautions** Impaired renal function: reduce dosage (see Data Sheet). Potentiation of oral anticoagulants, phenytoin and theophylline (see Data Sheet).



Prolonged treatment: observe patients periodically. Potential delay in diagnosis of gastric cancer (see Data Sheet). Care in patients with compromised bone marrow (see Data Sheet). Avoid during pregnancy and lactation. **Adverse reactions** Diarrhoea, dizziness, rash, tiredness. Gynaecomastia, occasional reversible liver damage, confusional states (usually in the elderly or very ill). Very rarely interstitial nephritis, acute pancreatitis, thrombocytopenia, headache, myalgia, arthralgia; very rare reports of alopecia, reversible impotence but no causal relationship established at usual therapeutic doses. **Legal category** POM. 4.3.85.

Smith Kline & French Laboratories Limited, Welwyn Garden City, Hertfordshire AL7 1EY.

SK&F

TG:AD1265

A MAJOR NEW UK TRIAL COLIFOAM v PREDNISOLONE ENEMA

THE FINAL VERDICT

PROVEN: Equal efficacy. PROVEN: Superior quality of life.

Although much has been published on the comparative efficacy and patient acceptance of COLIFOAM, the literature has until now lacked a comparison against prednisolone enemas.

That study has now been published.

The verdict? COLIFOAM is equal in efficacy to prednisolone enemas in the treatment of distal inflammatory bowel disease, but causes significantly less interference in patients' daily lives[1].

Analysis of the disturbance in social, sexual, occupational and routine outdoor activities all revealed statistically significant differences in favour of COLIFOAM.

COLIFOAM is also easier to retain than steroid enemas[1,2,3]. Retrograde spread has been shown to increase with the extent of disease[4] and COLIFOAM can reach well into the descending colon[5].

In distal inflammatory bowel disease. A better choice every time.

References (1) Somerville KW et al. (in press). (2) Ruddell WSJ et al. Gut 1980; 21:885-889. (3) Gaucher P and Champigneulle B. Journal Gastroenterol. Francais 1983;3:193-35. (4) Farthing MGJ et al. British Medical Journal 1979; 2:822-824. (5) Rhodes JM. Journal of Clinical & Hospital Pharmacy 1983;8:219-232. Prescribing Information. Presentation White odourless aerosol foam containing hydrocortisone acetate PhEur 10%. Uses Anti-inflammatory corticosteroid therapy for the topical treatment of ulcerative colitis, proctosigmoiditis and granular proctitis. Dosage and administration One applicatorful inserted into the rectum once or twice daily for two or three weeks and every second day thereafter. Shake can vigorously before use. (illustrated instructions are enclosed with every pack). Satisfactory response usually occurs within five to seven days. Contra-indications, warnings etc. Local contra-indications to the use of intrarectal steroids include obstruction, abscess, perforation, peritonitis, fresh intestinal anastomoses and extensive fistulae. General precautions common to all corticosteroid therapy should be observed during treatment with Colifoam. Treatment should be administered with caution in patients with severe ulcerative disease because of their predisposition to perforation of the bowel wall. Safety during pregnancy has not been fully established. Pharmaceutical precautions Pressurized container. Protect from sunlight and do not expose to temperatures above 50°C. Do not pierce or burn even after use. Do not refrigerate. Shake vigorously before use. Keep out of reach of children. For external use only. Legal category POM. Package quantities Aerosol canister containing 25g (approx. 14 applications) plus a plastic applicator and illustrated leaflet. Basic NHS cost 25g plus applicator, £7.25. Further Information One applicatorful of Colifoam provides a dose of approximately 125mg of hydrocortisone acetate, similar to that used in a retention enema, for the treatment of ulcerative colitis, sigmoiditis and proctitis. Product Licence No. 0036/0021. Further information is available on request. Stafford-Miller Ltd., Professional Relations Division, Hatfield, Herts. AL10 9NZ.

EASY EXAMINATIONS WITH NUBAIN* ANALGESIA



- ☐ strong, effective non-MDA analgesic, suitable for use during endoscopy or colonscopy and radiological and gynaecological investigations
- ☐ "ceiling" effect to respiratory depression reduces risks associated with opioid use[1]
- ☐ minimal effect on cardiac haemodynamics when used during catheterization[2]
- ☐ allows more accurate diagnosis of bile duct and gut obstructions due to minimal interference with function[3] and motility[4]

NUBAIN*

nalbuphine hydrochloride

Effective, comfortable analgesia during clinical investigations

Prescribing Information

Presentation: Nubain* Injection, 20mg of nalbuphine hydrochloride in 2ml ampoules.
Uses: For the relief of moderate to severe pain.
Dosage and Administration: 10-20mg for a 70kg individual, adjusted according to the severity of pain, physical status of the patient and concomitant medications. Nubain is not recommended for children.
Contra-indications: Hypersensitivity to Nubain.
Precautions and Warnings: Use with care in known and potential opioid abusers. Also care in active patients who may drive or operate machinery. Caution in patients with impaired respiration. Safety for use in myocardial infarction is not yet established. Caution and dose reduction in patients with impaired renal or hepatic function. Safe use not established in pregnancy and in conditions of raised intracranial pressure. Abrupt discontinuation of chronic therapy may produce withdrawal symptoms.
Side Effects: The most frequent reaction is sedation. Also sweating, nausea, vomiting, dizziness, dry mouth, vertigo and headache and other opioid effects may occur.
Product Licence No.: 4524/0003. **NHS Price:** £11.60 per box of 10 x 2ml ampoules.

References: 1. Julien RM. Effects of nalbuphine on normal and oxymorphone – depressed ventilatory responses to carbon dioxide challenge. Anaesthesiology 1982; 57: No 3A. 2. Fahmy NR, Sunder N, Soter NA. A comparison of histamine releasing properties and hemodynamic effects of morphine and nalbuphine in humans. Anesth Analg 1984;63:175. 3. Vatashsky E, Haskel Y. The effect of nalbuphine (Nubain®) compared to morphine and fentanyl on common bile duct pressure. Curr Ther Res 1985;37,1:95-102. 4. Shah M, Rosen M, Vickers MD. Effect of premedication and diazepam, morphine or nalbuphine on gastrointestinal motility after surgery. Br J. Anaesth. 1984;56: 1235-8.

Further information is available on request from Du Pont (UK) Limited, Pharmaceuticals, Wedgwood Way, Stevenage, Hertfordshire SG1 4QN. Telephone: (0438) 734549.

Du Pont Pharmaceuticals DU PONT

Created by Nature. Proven by Science.

For relief of irritable bowel and abdominal pain

The unique enteric-coated Colpermin capsule is a long-acting, slow-release product containing a thixotropic paste of peppermint oil. The enteric coating permits this naturally occurring medication to be delivered direct to the distal small bowel. Recent studies confirm that Colpermin offers direct relief to the patient by effectively relaxing intestinal smooth muscle to relieve colonic pain and gaseous distension.

- Irritable bowel symptoms are highly responsive to placebo, but in a recent double-blind cross-over trial, Colpermin was found to be superior to placebo in alleviating irritable bowel symptoms over a three-week period.[1]

- A delayed-release preparation, Colpermin reaches the colon in an unmetabolised state, allowing it to effectively reduce colonic motility.[2]

- Recent ultrasound studies show a consistent inhibitory effect of topical peppermint oil on colon motility and symptomatic improvement of irritable bowel patients given peppermint oil.[3]

References:

1. Rees WDW, Evans BK, Rhodes J: Treating irritable bowel syndrome with peppermint oil. *Br Med J* 2:835-836, 1979.

2. Somerville KW, Richmond CR, Bell GD: Delayed release peppermint oil capsules (Colpermin) for the spastic colon syndrome: A pharmacokinetic study. Proceedings of the British Pharmacological Society, Cambridge, April 1983. *Br J Clin Pharmacol*, to be published.

3. Taylor BA, Duthie HL, Oliveira RB, et al: Ultrasound used to measure the response of colonic motility to essential oils. Proceedings of *The International Motility Symposium* Aix-en-Provence, France, September 1983, to be published.

COLPERMIN™

(enteric-coated peppermint oil) CAPSULES



PRESCRIBING INFORMATION

Presentation: Enteric-coated gelatin capsule. Each contains 0.2 ml standardised peppermint oil B.P., Ph. Eur. **Uses:** For the treatment of symptoms of discomfort and of abdominal colic and distension experienced by patients with irritable bowel syndrome. **Dosage and Administration:** One capsule three times a day, preferably before meals and taken with a small quantity of water. The capsules should *not* be taken immediately after food. The dose may be increased to two capsules, three times a day when discomfort is more severe. The capsules should be taken until symptoms resolve, usually within one or two weeks. At times when symptoms are more persistent, the capsules can be continued for longer periods of between 2 to 3 months. There is no experience in the use of these capsules in children under the age of 15 years.

Tillotts LABORATORIES

Contraindications, Warnings, etc. Precautions: The capsule should not be broken or chewed. Patients who already suffer from heartburn, sometimes experience an exacerbation of these symptoms when taking the capsule. Treatment should be discontinued in these patients. **Adverse effects:** Heartburn, sensitivity reactions to menthol which are rare, and include erythematous skin rash, headache, bradycardia, muscle tremor and ataxia. **Product Licence:** PL 0424/0009. **Basic NHS Cost:** £10.58 per 100. UK and Foreign Patents pending. Colpermin is a trade mark of Tillotts Laboratories. Further information is available from Tillotts Laboratories, Henlow Trading Estate, Henlow, Beds.
European Patent No. 0015334. **UK Patent No. 2006011.**

Henlow Trading Estate, Henlow, Beds. SG16 6DS

Routine Upper GI Endoscopy Specifically

Olympus GIF-XQ10 OES OGD endoscope — small in size, big on performance.

The only routine gastroscope slim enough to pass through oesophageal tubes but give brilliant views and large biopsies.
Superb optical quality and a standard instrument channel, all combined in a slim 9.8mm insertion tube — increased patient tolerance with no compromise on diagnostic capabilities. Improvements in angulation have resulted in enhanced manoeuvrability — visualisation of the cardia and in the duodenal bulb is made even easier. Prove it for yourself — for a demonstration, contact our Medical Customer Liaison Department.



Specification	
Outer diameter	9.8mm
Channel diameter	2.8mm
Angulation	210° up/90° down 100° right/100° left Max. 240°
Working length	1025mm
Field of view	100°

OLYMPUS

KeyMed

Specialised Services to Medicine

KeyMed (Medical & Industrial Equipment) Ltd.
KeyMed House, Stock Road, Southend-on-Sea, SS2 5QH.
Telex: 995283, Telefax: (0702) 65677, Tel: (0702) 616333.

KeyMed (Ireland) Ltd.
KeyMed House, Lord Edward Court,
Bride Street, Dublin 8.

KeyMed Inc.
400 Airport Executive Park,
Spring Valley, New York, 10977.

Colofac is also indicated for the relief of gut spasm secondary to diverticular disease.

PRESCRIBING INFORMATION. PRESENTATION: White, sugar-coated tablets each containing 135 mg mebeverine hydrochloride. Available in packs of 100. Basic NHS price £8.35. INDICATIONS: 1. Irritable Bowel Syndrome. 2. Gastro-intestinal spasm secondary to organic diseases. DOSAGE AND ADMINISTRATION: Adults and children ten years and over: One tablet three times a day, preferably 20 minutes before meals. CONTRA-INDICATIONS, WARNINGS, ETC: Animal experiments have failed to show any teratogenic effects. However, the usual precautions concerning the administration of any drug during pregnancy should be observed. PRODUCT LICENCE NO: 512/0044.

duphar Further information is available upon request to the company.
Duphar Laboratories Ltd, Duphar House, Gaters Hill, West End, Southampton SO3 3JD. Tel: (0703) 472281

Concept and Evolution through Pilkington...



...UGI-3 Flexible Endoscope

Designed and built in Britain the UGI-3 Flexible Endoscope is the product of intense research and development. The result is an exceptional instrument with many advantageous characteristics more fully appreciable when in operation.

***Comfort and Ease of Use.** The latest developments in durable and lightweight materials have been applied throughout all stages of construction achieving a flexible, well-balanced instrument.

***Unique Bending Section.**

***Bright Imaging.** This allows clear visual examination and precise diagnosis.

***Compatible.** Suitable for most Cold Light Sources produced by recognised manufacturers by using a simple adaptor and via its 2.8mm biopsy channel the UGI-3 will accept almost all makes of biopsy forceps, cleaning or cytology brushes and washing tubes.



***After Sales Service – Guaranteed.** †A replacement endoscope will be made available to you within 48 hours of notification should your instrument not perform to your complete satisfaction.

(†Available to UK customers only)



Typical photographs obtained through a UGI-3 using a 35mm SLR Camera and no-lens coupling.

You can obtain further information on the Pilkington UGI-3 Flexible Endoscopes by contacting the Medical Sales Division at the address below:

PILKINGTON

◄ Medical Systems ►

The Focus of Medical Technology.

Pilkington Medical Systems Ltd. Bleasdale Court, 2 South Avenue, Clydebank Business Park, Clydebank G81 2LE. Telephone: 041-952 1111 · Telex: 776471

DE-NOL REBALANCES THE ULCER EQUATION

Prescribing Information De-Noltab and De-Nol
Presentation: De-Noltab is presented as flat round pink tablets, each tablet containing 120mg tri-potassium di-citrato bismuthate (calculated as Bi_2O_3). De-Nol is presented as a clear red liquid in a 560ml bottle containing 120mg tri-potassium di-citrato bismuthate (calculated as Bi_2O_3) in each 5ml. **Uses:** Ulcer healing agent. For the treatment of gastric and duodenal ulcers. **Dosage and administration:** By oral administration. Each tablet is to be crushed in the mouth and swallowed with a draught of water. Each dose of the liquid presentation is to be diluted with 15ml of water. ADULTS: One tablet or 5ml dose four times a day on an empty stomach, half an hour before each of the three main meals and two hours after the last meal of the day. The treatment course should be taken for the full 28 day period and it is important that a dose is not missed. If necessary, one further course of therapy may be given. Maintenance therapy with De-Noltab/De-Nol is not indicated. CHILDREN: As for adults. **Contra-indications, Warnings, etc:** De-Noltab and De-Nol should not be administered to patients with renal disorders, and on theoretical grounds the products are contra-indicated in pregnancy. SPECIAL PRECAUTIONS: De-Noltab and De-Nol may inhibit the efficacy of orally administered tetracyclines. SIDE EFFECTS: Blackening of the stool usually occurs. Darkening of the tongue, nausea and vomiting have been reported. OVERDOSAGE: No reports of overdosage have been received; gastric lavage and, if necessary, supportive therapy would be indicated. **Pharmaceutical precautions:** Normal pharmaceutical storage and handling are indicated. **Legal category:** P. **Package quantities:** DE-NOLTAB: Foil treatment packs of 112 tablets. DE-NOL: Treatment packs of 560ml. **Basic N.H.S. Price:** De-Noltab £15.84. De-Nol £10.31. **GMS Price (Eire):** De-Noltab IR£20.99. De-Nol IR£13.66. **Further information:** Some patients with an associated gastritis may experience an initial discomfort whilst taking De-Nol liquid. Milk should not be drunk by itself during the course of treatment as this can prevent the medicine from working properly. Small quantities of milk on a breakfast cereal or in tea or coffee taken with meals are permissible. Antacids should not be taken for half an hour before or half an hour after taking a dose of De-Noltab/De- Nol as these can interfere with the action of the drug. **Product Licence Numbers:** De-Noltab: 0166/0102. De-Nol: 0166/5024. **Product Authorisation Numbers:** De-Noltab: 62/22/1. De-Nol: 62/23/1.

SALAZOPYRIN® EN

sulphasalazine

HAS TOLERABILITY ALL WRAPPED UP

"Patients in whom sulfasalazine induces dyspeptic symptoms alone can be given EN Salazopyrin (entero-soluble) instead, and no more than 5% of these patients will be so troubled by dyspepsia that the treatment has to be discontinued."
Nielsen, O.H., Scand. J. Gastroenterol., 1982, 17, 389



Get them into the SALAZOPYRIN habit

DAY AFTER DAY AFTER YEAR

500mg q.i.d. in ulcerative colitis

PRESCRIBING INFORMATION

Dosage and Administration Plain or EN Tabs: In acute moderate attacks 2-4 tablets 4 times a day. In severe attacks give steroids also. Gradually reduce dose after 2-3 weeks to 3-4 tabs/day, given indefinitely. Suppositories: Two morning and night reducing dose after 3 weeks with improvement. Enema: One to be given at bedtime. Preparation contains adult dose. Children: Reduce adult dose on basis of bodyweight.

Contra-Indications Sensitivity to salicylates and sulphonamides. Infants under 2 years. Enema: Sensitivity to parabens.

Adverse Reactions Side effects common to salicylates or sulphonamides may occur. Most commonly these are nausea, loss of appetite and raised temperature which may be relieved on reduction of dose: use of EN tablets, enema or suppositories. If serious reactions occur the drug should be discontinued. Rare Adverse Reactions. Haematological: haemolytic anaemia, agranulocytosis, aplastic anaemia. Hypersensitivity: eg rash, fever. Gastrointestinal: eg stomatitis, impaired folate uptake. C.N.S.: eg peripheral neuropathy. Fertility: eg reversible oligospermia. Renal: eg proteinuria, crystalluria. Also: Stevens-Johnson syndrome and lung complications: eg fibrosing alveolitis.

Precautions Care in porphyria, allergic, renal or hepatic disease. Glucose 6-PD deficiency. Blood checks initially and periodically.

Pregnancy and Lactation While the ingestion of drugs in these situations may be undesirable, the severe exacerbations of the disease which can occur commends the continuance of therapy. Long clinical usage and experimental studies have failed to reveal teratogenic or ictenic hazards. The amounts of drug present in the milk should not present a risk to a healthy infant.

Packages and Prices Plain Tablets (0.5g): 100 & 500: £6.70 for 100. EN Tablets (0.5g): 100 & 500: £8.70 for 100. Suppositories (0.5g): 10 & 50: £2.80 for 10. Enemas (3.0g): 7: £12.10 for 7.
Product Licence Numbers Plain Tablets: 0009/5006. EN Tablets: 0009/5007. Suppositories: 0009/5008. Enema: 0009/5009.

Pharmacia

Further information is available on request from: Pharmacia Limited, Pharmacia House, Midsummer Boulevard, Milton Keynes MK9 3HP. Telephone: Milton Keynes (0908) 661101.

AN IN-DEPTH LOOK AT THE NEW IMMERSIBLES FROM PENTAX.



Fully immersible

Compact, lightweight, high-technology instruments set new standards in endoscopy design

Fully immersible for easy care and maintenance

Pentax introduces a major new range of endoscopes offering a level of performance and quality far in advance of anything currently available.

Every model is fully immersible, making disinfection a fuss-free and simple procedure.

The range incorporates new innovations in every area of endoscope design and is the result of years of intensive research into micro optical engineering.

Clearer, brighter viewing with increased image area

The superb viewing system incorporates up to twice as many fibres in the bundle to give a sharper, brighter, bigger image.

Together with a generally wider field of view and excellent distal tip control, the new Pentax models enhance both diagnostic and therapeutic procedures.

Total compatibility with full service support

The new Pentax immersibles are compatible with existing ancillary equipment and there is a full range of accessories to meet every requirement.

Pentax have also laid great emphasis on servicing and maintenance to provide a back up service that is as effective and efficient as the instruments themselves.

Nothing less than a full in-depth clinical demonstration can show how far ahead Pentax are.

Seeing is believing!

PENTAX

PENTAX WORLD-WIDE
ASAHI OPTICAL CO. LTD.
Maeno-cho 2-36-9, Itabashi-ku,
Tokyo, Japan. Tel: (03) 960-5151. Telex: 272-2331 PENTAX J.
PENTAX PRECISION INSTRUMENT CORPORATION
30 Ramland Road, Orangeburg, NY 10962-2699, USA.
Tel: (914) 365-0700. TOLL-FREE (800) 431-5880.

ASAHI OPTICAL (INT'L) LTD.
General Garment Building, 6th Fl.
100-110 Kwai Cheong Road, Kwai Chung NT.
Hong Kong. Tel: 0-244021. Telex: 45086 AO1 HX.
PENTAX HANDELSGESELLSCHAFT GmbH
Julius Vosseler Strasse 104, 2000 Hamburg 54.
West Germany. Tel: 040 56 170. Telex: 215016 PENTAX D.

Pentax U.K. Limited,
Pentax House,
South Hill Avenue,
South Harrow,
Middlesex,
HA2 0LT
Tel: 01-864 4422

MEDICAL DIVISION

NEW

ANNOUNCING

ASACOL™

(MESALAZINE)

"This preparation is an important advance in the management of colitis since it may be given to patients unable to take sulphasalazine. . . ."[1]

For full prescribing information see overleaf

Tillotts LABORATORIES

NEW

ASACOL™

(MESALAZINE)

For the maintenance of remission in patients with ulcerative colitis who cannot tolerate sulphasalazine.

Asacol delivers only 5-amino salicylic acid and is effective in maintaining clinical remission in patients with ulcerative colitis[1].

Asacol provides efficacy comparable to sulphasalazine, but with considerably less side effects[3].

Asacol tablets have a patented acrylic-based resin coating that enables them to remain intact until all the active ingredient is released in the colon[2].

Asacol is specifically recommended for ulcerative colitis patients who have difficulty tolerating sulphasalazine.

Mesalazine is the British-approved name for 5-amino salicylic acid.



Radiograph taken five hours after convalescent patients ingested Asacol in capsule form containing barium, showing them to be intact in the terminal ileum.[2]

Radiograph of the same patient after eight hours, showing broken capsules in the ascending colon.

References:

1. Dew MJ, Hughes P, Harries AD, et al: Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. *Br Med J* 285:1012-1014, 1982.

2. Dew MJ, Hughes PJ, Lee MG, et al: An oral preparation to release drugs in the human colon. *Br J Clin Pharmacol* 14:405-408, 1982.

3. Dew MJ, Harries AD, Evans BK, Rhodes J, et al: Treatment of ulcerative colitis with oral 5-aminosalicylic acid in patients unable to take sulphasalazine. *The Lancet* October 1, 1983 p.801.

ABBREVIATED PRESCRIBING INFORMATION

PRESENTATION
Red tablets containing 400mg of mesalazine (5-amino salicylic acid) coated for release in the terminal ileum and colon.

USES
For the maintenance of remission of ulcerative colitis in patients who cannot tolerate sulphasalazine.

DOSAGE AND ADMINISTRATION
Adults: 3 to 6 tablets daily in divided doses
There is no dose recommendation for children.

CONTRA-INDICATIONS, WARNINGS, ETC.
Contra-Indications
Contra-indications: a history of sensitivity to salicylates. Children under 2 years of age

Precautions
Renal disorder. Mesalazine is excreted rapidly by the kidney mainly as its metabolite, N acetyl 5 amino salicylic acid. In rats large doses of mesalazine injected intravenously produce tubular and glomerular toxicity. Although no renal toxicity has been reported in patients taking Asacol, it is not recommended in patients with renal impairment and caution should be exercised in patients with a raised blood urea or proteinuria.

Asacol should not be given with lactulose or similar preparations which lower stool pH and may prevent release of mesalazine.

Adverse Reactions
Adverse reactions occur in a small proportion of patients who previously could not tolerate sulphasalazine. The side-effects are predominantly gastrointestinal (nausea, diarrhoea and abdominal pain) and headache. Asacol may be associated with the exacerbation of the symptoms of colitis in those patients who have previously had such problems with sulphasalazine.

Other side effects observed with sulphasalazine such as depression of bone marrow and of sperm count and function, have not been reported with Asacol.

LEGAL CATEGORY: POM
PL: 0424/0032
Basic NHS Price: £21.85/100 tablets

U.K. Patent No. 8322387

Tillotts LABORATORIES

Henlow Trading Estate, Henlow, Beds. SG16 6DS.

Sigmoidoscopes: Take a Good Look at the Alternative.

- Fuji are the largest photo optical company in the world.
- Fuji's immense research and development resources have resulted in instruments which are second-to-none.
- Fuji Sigmoidoscopes are guaranteed for 18 months, including accidental damage within the first 12 months.
- Fuji Sigmoidoscopes are serviced by Pyser Ltd, – an established UK company with 50 years' experience in sophisticated optical systems.
- Pyser's factory trained service engineers always deliver on time – no ifs or buts.
- Pyser staff are efficient, courteous and friendly – we never take our customers for granted.

FUJINON

Fujinon Fibrescopes
Pyser Ltd., Fircroft Way,
Edenbridge, Kent TN8 6HA.
Edenbridge (0732) 864111 (8 lines)